VKVishal Kukreti

Vishal Kukreti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vishal Kukreti has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Christine Chen

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada

    3 shared publications
  • Donna E. Reece

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada

    2 shared publications
  • Suzanne Trudel

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada

    2 shared publications
  • Victor H. Jimenez‐Zepeda

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada

    2 shared publications
  • Ahmed Rabea

    Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt

    1 shared publication
  • Andrew Winter

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada

    1 shared publication

Latest Publications

  • Open Access

    Rituximab-Induced Coronary Vasospasm

    by Linda Lee, Vishal Kukreti

    Rituximab has improved the treatment of B-cell non-Hodgkin lymphomas. While it is generally well tolerated, serious adverse effects including infusion reactions with hemodynamic compromise and cardiac arrhythmias or ischemia are possible. We report a case of coronary vasospasm occurring during a rituximab infusion in a patient with minimal tumour burden and who had no cardiac risk factors. This case highlights that determination of the cause of ischemia is important and may identify some patients who can be successfully rechallenged.


  • Open Access

    Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy

    by Victor H. Jimenez‐Zepeda, Suzanne Trudel, Andrew Winter, Donna E. Reece, Christine Chen, Vishal Kukreti


  • Open Access

    Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation

    by Victor H. Jimenez‐Zepeda, Suzanne Trudel, Donna E. Reece, Christine Chen, Ahmed M. Rabea, Vishal Kukreti

    High‐dose chemotherapy with autologous stem cell transplantation (ASCT) can achieve excellent clinical responses in patients with POEMS syndrome (Jimenez Zepeda et al., Blood 2010;116:2403; Gertz et al., Am J Hematol 2005;79:319–328; Gherardi et al., Ann Neurol 1994;35:501–505; Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Salem et al., J Immunol 2009;182:2030–2040; Salem et al., Cancer Immunol Immunother 2010;59:341–353; Salem et al., Cell Immunol 2010;261:134–143). However, High‐dose melphalan with ASCT should be considered carefully due to its treatment‐related morbidity (Vuckovic et al., Blood 2003;101:2314–2317), especially in patients with poor performance status owing to polyneuropathy and multiorgan involvement, such as cardiac, respiratory, and renal failure. Significant increases in the concentration of circulating macrophage colony‐stimulating factor, erythropoietin, IL‐6, and TNF‐α, reach near maximal values at approximately day +12, predating neutrophil engraftment, and clinically manifest with fever, rash and edema (Dispenzieri et al., Eur J Haematol 2008;80:397–406). Depending on the definition used, ∼50% of patients satisfied criteria for engraftment syndrome (ES) (Vuckovic et al., Blood 2003;101:2314–2317). ES occurs in 27–47% of patients who undergo ASCT; mortality rate is reported from 8% to 18% (Gattinoni et al., Nat Rev Immunol 2006;6:383–393; Vuckovic et al., Blood 2003;101:2314–2317). We have therefore reviewed our experience with ASCT in patients with POEMS syndrome who were treated with cyclophosphamide and prednisone as induction therapy followed by cyclophosphamide mobilization with an emphasis on treatment‐related morbidity and frequency of ES. Our study confirms that ASCT is a feasible and efficacious treatment for patients with POEMS syndrome. In addition, the use of CP followed by cyclophosphamide mobilization decreases the incidence of PES leading to less morbidity and mortality rates. Am. J. Hematol. 2011.


  • Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature

    by David Telio, Denis Bailey, Christine Chen, Michael Crump, Donna Reece, Vishal Kukreti

    Light chain (AL) amyloidosis has a rare association with non-Hodgkin lymphoma (NHL). Both peritumoral and systemic AL amyloidosis have been reported, but a detailed description of these syndromes is lacking. We describe 10 patients with lymphoma associated AL amyloidosis. NHL patients with peritumoral amyloidosis had low or undetectable levels of monoclonal (M) protein, mostly single organ involvement(lung or soft tissue), and underlying extranodal marginal zone lymphoma, mucosa associated lymphoid tissue subtype. NHL patients with systemic amyloidosis had high levels of M-protein, multiorgan involvement with frequent cardiac involvement, and predominantly underlying lymphoplasmacytic lymphoma. Systemic amyloidosis was associated with inferior outcomes